tiprankstipranks
Advertisement
Advertisement

ELVN Stock Latest News

Why Is Enliven Therapeutics Stock (ELVN) Up Today?
Market NewsWhy Is Enliven Therapeutics Stock (ELVN) Up Today?
1h ago
ELVN
Enliven rises 9.9%
PremiumThe Fly
Enliven rises 9.9%
3h ago
ELVN
Enliven 8.9M share Spot Secondary priced at $37.50
PremiumThe Fly
Enliven 8.9M share Spot Secondary priced at $37.50
8h ago
ELVN
Enliven announces $250M common stock offering
PremiumThe Fly
Enliven announces $250M common stock offering
23h ago
ELVN
Midday Fly By: Oracle slides, SpaceX on deck for public debut
PremiumThe Fly
Midday Fly By: Oracle slides, SpaceX on deck for public debut
1d ago
GD
MH
Boris Peaker Reiterates Buy Rating and $45 Price Target on ELVN-001 After Strong Phase 1b CML Data Support Best-in-Class Potential
PremiumRatingsBoris Peaker Reiterates Buy Rating and $45 Price Target on ELVN-001 After Strong Phase 1b CML Data Support Best-in-Class Potential
1d ago
ELVN
Enliven rises 14.8%
Premium
The Fly
Enliven rises 14.8%
1d ago
ELVN
Enliven advances ELVN-001 with positive Phase 1 data
Premium
Company Announcements
Enliven advances ELVN-001 with positive Phase 1 data
1d ago
8K
ELVN
Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial
PremiumThe Fly
Enliven up 15% to $42.50 after positive data from Phase 1 ENABLE trial
1d ago
ELVN
Enliven’s ELVN-001 shows efficacy in Phase 1 myeloid leukemia trial
PremiumThe Fly
Enliven’s ELVN-001 shows efficacy in Phase 1 myeloid leukemia trial
1d ago
ELVN
Enliven Therapeutics Expands Authorized Shares After Stockholder Vote
PremiumCompany Announcements
Enliven Therapeutics Expands Authorized Shares After Stockholder Vote
2d ago
8K
ELVN
Toll Brothers upgraded, Lennar downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Toll Brothers upgraded, Lennar downgraded: Wall Street’s top analyst calls
3d ago
AJG
AVB
Enliven initiated with a Buy at Stifel
PremiumThe FlyEnliven initiated with a Buy at Stifel
4d ago
ELVN
Analyst Raises Price Target to $59 and Reaffirms Buy on ELVN-001’s Differentiated CML Opportunity
Premium
Ratings
Analyst Raises Price Target to $59 and Reaffirms Buy on ELVN-001’s Differentiated CML Opportunity
7d ago
ELVN
Enliven price target raised to $62 from $45 at Mizuho
Premium
The Fly
Enliven price target raised to $62 from $45 at Mizuho
10d ago
ELVN
Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning
PremiumRatings
Boris Peaker Reiterates Buy Rating on ELVN-001 with Unchanged $45 Price Target, Citing Strong Clinical Data and Strategic Positioning
1M ago
ELVN
Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress
PremiumThe Fly
Enliven to presents Phase 1 clinical trial data for ELVN-100 at EHA Congress
1M ago
ELVN
Guggenheim starts Enliven with Buy on leukemia opportunity
PremiumThe Fly
Guggenheim starts Enliven with Buy on leukemia opportunity
1M ago
ELVN
Enliven initiated with a Buy at Guggenheim
PremiumThe Fly
Enliven initiated with a Buy at Guggenheim
1M ago
ELVN
Enliven price target raised to $59 from $41 at Goldman Sachs
PremiumThe FlyEnliven price target raised to $59 from $41 at Goldman Sachs
1M ago
ELVN
Phil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029
Premium
Ratings
Phil Nadeau Reiterates Buy on Enliven, Citing Strong ELVN-001 Early Data, Clear Pivotal Path, and Solid Cash Runway to 2029
1M ago
ELVN
Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
Premium
Ratings
Needham’s Boris Peaker Reiterates Buy on Enliven, Citing Strong ELVN-001 Efficacy in CML and Pivotal Phase 3 ENABLE-2 Catalyst Pathway
1M ago
ELVN

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >